JPWO2022246084A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022246084A5
JPWO2022246084A5 JP2023571758A JP2023571758A JPWO2022246084A5 JP WO2022246084 A5 JPWO2022246084 A5 JP WO2022246084A5 JP 2023571758 A JP2023571758 A JP 2023571758A JP 2023571758 A JP2023571758 A JP 2023571758A JP WO2022246084 A5 JPWO2022246084 A5 JP WO2022246084A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
set forth
acid sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521098A (ja
JP2024521098A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030068 external-priority patent/WO2022246084A1/en
Publication of JP2024521098A publication Critical patent/JP2024521098A/ja
Publication of JPWO2022246084A5 publication Critical patent/JPWO2022246084A5/ja
Publication of JP2024521098A5 publication Critical patent/JP2024521098A5/ja
Pending legal-status Critical Current

Links

JP2023571758A 2021-05-20 2022-05-19 SARS-CoV-2ポリペプチド Pending JP2024521098A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163190964P 2021-05-20 2021-05-20
US63/190,964 2021-05-20
US202263341771P 2022-05-13 2022-05-13
US63/341,771 2022-05-13
PCT/US2022/030068 WO2022246084A1 (en) 2021-05-20 2022-05-19 Sars-cov-2 polypeptides

Publications (3)

Publication Number Publication Date
JP2024521098A JP2024521098A (ja) 2024-05-28
JPWO2022246084A5 true JPWO2022246084A5 (https=) 2025-05-28
JP2024521098A5 JP2024521098A5 (https=) 2025-05-28

Family

ID=82321637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571758A Pending JP2024521098A (ja) 2021-05-20 2022-05-19 SARS-CoV-2ポリペプチド

Country Status (10)

Country Link
US (1) US20220370601A1 (https=)
EP (1) EP4294440A1 (https=)
JP (1) JP2024521098A (https=)
KR (1) KR20240012394A (https=)
AU (1) AU2022277697A1 (https=)
BR (1) BR112023024034A2 (https=)
CA (1) CA3212678A1 (https=)
IL (1) IL308465A (https=)
MX (1) MX2023013665A (https=)
WO (1) WO2022246084A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240042070A1 (en) * 2022-06-28 2024-02-08 Transcode Therapeutics, Inc. Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy
CN115947801B (zh) * 2022-12-29 2026-02-06 中国疾病预防控制中心病毒病预防控制所 一种流感病毒通用和冠状病毒联合多肽及其疫苗的应用
CN116143908A (zh) * 2023-02-10 2023-05-23 武汉华美生物工程有限公司 一种针对VLPs类型抗原免疫产生高效价抗血清的方法
WO2025231068A1 (en) * 2024-04-30 2025-11-06 The Regents Of The University Of Michigan Compositions and methods for enhancing systemic and mucosal immune responses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
EP4132576A1 (en) * 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
EP4138876A1 (en) * 2020-04-23 2023-03-01 ISA Pharmaceuticals B.V. Immunization against sars-cov-related diseases
GB202011652D0 (en) * 2020-07-28 2020-09-09 Univ Oxford Innovation Ltd Polypeptide panels and uses thereof
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19

Similar Documents

Publication Publication Date Title
WO2020254535A1 (en) Rotavirus mrna vaccine
US20240370011A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
CA2406100A1 (en) Dna transfection system for the generation of infectious influenza virus
JP2019519252A5 (https=)
US20110110974A1 (en) Methods and kits for inducing a ctl response using a prime boost regimen
JP2002537844A (ja) ヘルパーウイルス無しで安定な組換えインフルエンザウイルス
CN111108192A (zh) 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途
JP2020530765A5 (https=)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2020536489A5 (https=)
JP2008514203A5 (https=)
US12280104B2 (en) Composition and methods for MRNA vaccines against novel omicron coronavirus infections
US20250339510A1 (en) Polynucleotide vaccine formulations and methods of using the same
CN113633764B (zh) 一种含佐剂的新冠dna疫苗
TWI901715B (zh) 大猩猩腺病毒核酸及胺基酸序列,包含彼之載體,及其用途
JPWO2022246084A5 (https=)
WO2022260960A1 (en) Virus-like particle vaccine for coronavirus
JPWO2019016680A5 (https=)
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
WO2005056051A2 (en) Hepatitis b vaccines and compositions
CN117203243A (zh) 用于预防rsv和piv3感染的组合物和方法
US20230201330A1 (en) Virus-like particles containing RSV antigen protein and vaccines using the same
CN112135908A (zh) 选择性cd8阳性t细胞诱导疫苗抗原
CA2325345A1 (en) Medicaments for inducing cytotoxic t-cells
CN119264229A (zh) 基于SARS-CoV-2的不同奥密克戎变异型的S蛋白的疫苗和组合物